| 0.6419 0.012 (1.89%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.9 | 1-year : | 1.03 |
| Resists | First : | 0.77 | Second : | 0.88 |
| Pivot price | 0.65  |
|||
| Supports | First : | 0.6 | Second : | 0.49 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.67 |
| MA(100) : | 0.89 |
MA(250) : | 1.11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 18.5 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 2.75 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HKPD ] has closed above bottom band by 36.1%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.66 |
| Low: | 0.61 - 0.62 | 0.62 - 0.62 |
| Close: | 0.64 - 0.64 | 0.64 - 0.65 |
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers custom clearance, drugs enlisting, warehouse, and other logistics services. The company serves e-commerce platform logistics partners, merchants, and pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Fri, 13 Feb 2026
12 Industrials Stocks Moving In Friday's Pre-Market Session - Benzinga
Sat, 17 Jan 2026
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - The Manila Times
Fri, 16 Jan 2026
Cellyan Biotechnology receives Nasdaq minimum bid price deficiency notice - Investing.com
Wed, 17 Dec 2025
Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders - ChartMill
Wed, 03 Dec 2025
Insiders Who Purchased US$6.90m Of Hong Kong Pharma Digital Technology Holdings Stock May Not Have Expected 19% Tumble - simplywall.st
Tue, 26 Aug 2025
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 11 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 133 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 27 (K) |
| EPS | -0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | -0.2 % |
| Operating Margin | -9.1 % |
| Return on Assets (ttm) | 1.3 % |
| Return on Equity (ttm) | -0.6 % |
| Qtrly Rev. Growth | -4.7 % |
| Gross Profit (p.s.) | 0.21 |
| Sales Per Share | 1.84 |
| EBITDA (p.s.) | 0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 1.42 |
| Price to Sales | 0.34 |
| Price to Cash Flow | 12.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|